Biostem Technologies Inc
OTC:BSEM
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.77
24.98
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BSEM stock under the Base Case scenario is 11.83 USD. Compared to the current market price of 19.85 USD, Biostem Technologies Inc is Overvalued by 40%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Biostem Technologies Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BSEM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Biostem Technologies Inc
Balance Sheet Decomposition
Biostem Technologies Inc
Current Assets | 88.1m |
Cash & Short-Term Investments | 6.6m |
Receivables | 78.2m |
Other Current Assets | 3.3m |
Non-Current Assets | 2.4m |
PP&E | 1.8m |
Intangibles | 530.5k |
Other Non-Current Assets | 50k |
Current Liabilities | 72m |
Accounts Payable | 4.6m |
Accrued Liabilities | 1.8m |
Other Current Liabilities | 65.6m |
Non-Current Liabilities | 378k |
Long-Term Debt | 378k |
Other Non-Current Liabilities | 10 |
Earnings Waterfall
Biostem Technologies Inc
Revenue
|
131.4m
USD
|
Cost of Revenue
|
-6.9m
USD
|
Gross Profit
|
124.5m
USD
|
Operating Expenses
|
-112.8m
USD
|
Operating Income
|
11.8m
USD
|
Other Expenses
|
-3.9m
USD
|
Net Income
|
7.9m
USD
|
Free Cash Flow Analysis
Biostem Technologies Inc
USD | |
Free Cash Flow | USD |
BSEM Profitability Score
Profitability Due Diligence
Biostem Technologies Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Biostem Technologies Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
BSEM Solvency Score
Solvency Due Diligence
Biostem Technologies Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
Biostem Technologies Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BSEM Price Targets Summary
Biostem Technologies Inc
According to Wall Street analysts, the average 1-year price target for BSEM is 24.74 USD with a low forecast of 24.49 USD and a high forecast of 25.46 USD.
Dividends
Current shareholder yield for BSEM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.
Contact
IPO
Employees
Officers
The intrinsic value of one BSEM stock under the Base Case scenario is 11.83 USD.
Compared to the current market price of 19.85 USD, Biostem Technologies Inc is Overvalued by 40%.